SEC Tracker
Get the app

Vistagen Therapeutics VTGN

Vistagen Therapeutics FY 2026: net loss $69.7M; diluted EPS −$1.83

Form
10-K
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Vistagen Therapeutics reported for the year ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$69.7MAgainst −$51.4M in FY 202510-K income statement, on EDGAR
  2. Diluted EPS−$1.83Against −$1.67 in FY 202510-K income statement, on EDGAR
  3. Cash and cash equivalents$30.8M−54% from $67.1M in FY 2025Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations−$66.4MAgainst −$42.1M in FY 202510-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Vistagen Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Agenus AGEN public float $135M, Jun 30, 2025
  2. Voyager Therapeutics VYGR public float $144M, Jun 30, 2025
  3. Eledon Pharmaceuticals ELDN public float $145M, Jun 30, 2025
  4. Puma Biotechnology PBYI public float $145M, Jun 30, 2025
  5. Neurogene NGNE public float $146M, Jun 30, 2025